Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in mo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Joly, Véronique, Moroni, Mauro, Concia, Ercole, Lazzarin, Adriano, Hirschel, Bernard, Jost, Josef, Chiodo, Francesco, Bentwich, Zvi, Love, W. Campbell, Hawkins, David A., Wilkins, Edmund G. L., Gatell, Aritigas J., Vetter, Norbert, Greenwald, Cynthia, Freimuth, William W., de Cian, Wanda
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2000
Sujets:
Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC101620/
https://ncbi.nlm.nih.gov/pubmed/11036040
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires